Orally available pharmaceutical formulation suitable for improved management of movement disorders

Orally available pharmaceutical formulation suitable for improved management of movement disorders

The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kreilgaard, Mads, Mikkelsen, Jens D, Thomsen, Mikael S, Nielsen, Peter Gudmund, Hansen, John Bondo
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Kreilgaard, Mads
Mikkelsen, Jens D
Thomsen, Mikael S
Nielsen, Peter Gudmund
Hansen, John Bondo
description The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US10561618B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US10561618B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US10561618B23</originalsourceid><addsrcrecordid>eNqNjUsKAjEQBbNxIeod2gMIRnFwrSjuXKjroWfSGQOdD_kMeHvD4AFcvaIoeHPR3SMyfwBHNIwdE4Q3Ros9lWx6ZNA-2sKYjXeQislTUyUYG6IfSYFFhwNZchm8BlvdxMokHxXFtBQzjZxo9duFWF8vz_NtQ8G3lEL9cpTb10NuD41s5PG02__TfAH4wT9u</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Orally available pharmaceutical formulation suitable for improved management of movement disorders</title><source>esp@cenet</source><creator>Kreilgaard, Mads ; Mikkelsen, Jens D ; Thomsen, Mikael S ; Nielsen, Peter Gudmund ; Hansen, John Bondo</creator><creatorcontrib>Kreilgaard, Mads ; Mikkelsen, Jens D ; Thomsen, Mikael S ; Nielsen, Peter Gudmund ; Hansen, John Bondo</creatorcontrib><description>The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20200218&amp;DB=EPODOC&amp;CC=US&amp;NR=10561618B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20200218&amp;DB=EPODOC&amp;CC=US&amp;NR=10561618B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Kreilgaard, Mads</creatorcontrib><creatorcontrib>Mikkelsen, Jens D</creatorcontrib><creatorcontrib>Thomsen, Mikael S</creatorcontrib><creatorcontrib>Nielsen, Peter Gudmund</creatorcontrib><creatorcontrib>Hansen, John Bondo</creatorcontrib><title>Orally available pharmaceutical formulation suitable for improved management of movement disorders</title><description>The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjUsKAjEQBbNxIeod2gMIRnFwrSjuXKjroWfSGQOdD_kMeHvD4AFcvaIoeHPR3SMyfwBHNIwdE4Q3Ros9lWx6ZNA-2sKYjXeQislTUyUYG6IfSYFFhwNZchm8BlvdxMokHxXFtBQzjZxo9duFWF8vz_NtQ8G3lEL9cpTb10NuD41s5PG02__TfAH4wT9u</recordid><startdate>20200218</startdate><enddate>20200218</enddate><creator>Kreilgaard, Mads</creator><creator>Mikkelsen, Jens D</creator><creator>Thomsen, Mikael S</creator><creator>Nielsen, Peter Gudmund</creator><creator>Hansen, John Bondo</creator><scope>EVB</scope></search><sort><creationdate>20200218</creationdate><title>Orally available pharmaceutical formulation suitable for improved management of movement disorders</title><author>Kreilgaard, Mads ; Mikkelsen, Jens D ; Thomsen, Mikael S ; Nielsen, Peter Gudmund ; Hansen, John Bondo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US10561618B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Kreilgaard, Mads</creatorcontrib><creatorcontrib>Mikkelsen, Jens D</creatorcontrib><creatorcontrib>Thomsen, Mikael S</creatorcontrib><creatorcontrib>Nielsen, Peter Gudmund</creatorcontrib><creatorcontrib>Hansen, John Bondo</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Kreilgaard, Mads</au><au>Mikkelsen, Jens D</au><au>Thomsen, Mikael S</au><au>Nielsen, Peter Gudmund</au><au>Hansen, John Bondo</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Orally available pharmaceutical formulation suitable for improved management of movement disorders</title><date>2020-02-18</date><risdate>2020</risdate><abstract>The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US10561618B2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Orally available pharmaceutical formulation suitable for improved management of movement disorders
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A19%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Kreilgaard,%20Mads&rft.date=2020-02-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS10561618B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true